MedTrace Logo

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

NCT05489328 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 394

Last updated 2024-04-18

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to describe the safety and immunogenicity of Pneumococcal Conjugate Formulations in healthy adults 18 through 49 years of age.

Conditions

  • Pneumococcal Disease

Interventions

OTHER

Candidate-1

Biological

OTHER

Candidate-2

Biological

OTHER

Candidate-3

Biological

OTHER

Candidate-4

Biological

OTHER

Candidate-5

Biological

OTHER

Candidate-6

Biological

OTHER

Candidate Control

Biological

BIOLOGICAL

13vPnC

13-valent pneumococcal conjugate vaccine

BIOLOGICAL

PCV15

15-valent pneumococcal conjugate vaccine

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-15
Primary Completion
2022-10-07
Completion
2022-10-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05489328 on ClinicalTrials.gov